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Antitumoral Effects of Metformin 
in Ovarian Cancer
Maritza P. Garrido, Margarita Vega and Carmen Romero
Abstract
In the last years, the antidiabetic drug metformin has received considerable 
attention in pursuing new drugs for anticancer treatments. Several reports have 
shown that metformin would have antitumor effects, not only attributable to its 
systemic effects but also due to direct effects on tumor cells. It has been proposed 
that metformin could be a suitable alternative for the treatment of gynecological 
cancers, such as ovarian cancer. This disease is characterized by high cell prolifera-
tion and angiogenesis potential, because ovarian cancer cells overexpress most 
oncogenic molecules including growth factors. The aim of the present chapter is to 
discuss the molecular mechanism by which metformin would affect tumor cells, 
with focus on epithelial ovarian cancer.
Keywords: metformin, ovarian cancer, cell proliferation, angiogenesis, growth 
factors, AMPK
1. Introduction
Metformin or 1,1-dimethylbiguanide is a derivate of isoamylene guanidine, a 
substance found in the plant Galega officinalis [1]. This drug is widely used in meta-
bolic disorders as type 2 diabetes mellitus, metabolic syndrome, and gestational 
diabetes [2, 3]. Besides, metformin is used as a treatment for polycystic ovarian 
syndrome [4], which is characterized by the dysfunction of reproductive tissues 
such as the ovary and endometrium. In this context, metformin improves ovarian 
follicle dynamics and frequency of ovulation [5, 6], and it increases the expression 
of endometrial GLUT4 (insulin-regulated glucose transporter), which may improve 
endometrial physiology in these patients [7].
In the last decades, metformin has been studied in the context of cancer, 
especially after an initial report by Evans et al., performed with a Scottish data-
base, who found that metformin intake reduces the risk of cancer in type 2 diabetic 
patients [8].
Type 2 diabetes and obesity affect a significant percentage of the world 
population [9, 10] whose food habits and lifestyle have been changing in the last 
decades. Both obesity and type 2 diabetes are pathologies associated with increased 
incidence and poor prognosis of ovarian cancer by several authors [11–13]. These 
observations could be explained because obesity and type 2 diabetes are charac-
terized by molecular changes that could encourage tumoral transformation and 
progression, such as hyperinsulinemia, hyperglycemia, dyslipidemia, increased 
insulin-like growth factors (IGF), adipose tissue factors, and inflammatory 
components [14–19].
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By its chemical nature, metformin gets into the cell through organic cation 
transporters (OCTs) and multidrug and toxin extrusion transporters [20]. Because 
metformin cannot be metabolized, almost its entirety is excreted by the kidneys; the 
plasmatic levels of this drug do not reflect its intracellular concentration, mainly by 
its high apparent volume of distribution and prolonged half-life [21, 22]. Therefore, 
metformin is accumulated in tissues, and its plasmatic concentration is probably 
lower than of organs that express OCT transporters. This observation supports 
most in vitro studies that use high concentrations of metformin to study its antitu-
moral properties. Importantly, these transporters are present in the ovary [23, 24], 
so ovarian cancer cells could be a target for metformin action.
2. Indirect antitumoral effects of metformin in cancer
It is discussed that metformin could display direct and indirect antitumoral 
effects. The systemic effects of this drug include the decrease of blood glucose and 
insulin levels by action in its classical target organs: liver, muscle, and fat tissues. 
In humans, metformin decreases the hepatic gluconeogenesis and the release of 
glucose from hepatic reserves, which produces an increase in the peripheral uptake 
of glucose and its metabolism, decreasing patients’ hyperglycemia and hyper-
insulinemia [1, 2, 25]. These conditions (hyperglycemia and hyperinsulinemia) 
favor tumoral growth and are associated with cancer incidence, by two possible 
mechanisms: (1) high availability of glucose for cancer cells and (2) high levels of 
insulin, which could act in insulin-like growth factor (IGF) receptors [14–16]. IGF/
IGF receptors display an important role in the ovary, because 100% of the ovarian 
carcinomas express IGF receptors [26].
In fat tissue, metformin decreases the activity of lipogenic enzymes such as 
HMG-CoA reductase, acetyl-CoA carboxylase (ACC), and fatty acid synthase, 
decreasing the endogen production of cholesterol and the fatty acid synthesis [1, 27, 
28]. This produces a decrease in the plasma levels of lipids in patients using metfor-
min [29–32], which in addition to metformin-hypoglycemic properties, decreases 
the readiness of energy substrates of tumoral cells.
All these metformin-mediated changes impair survival and mitogenic signaling 
and decrease nutrient availability for ovarian cancer cells.
3. Effects of metformin in ovarian cancer
3.1 Direct effects of metformin in ovarian cancer cells: role of AMPK
Several studies have shown that metformin displays direct antitumoral effects. 
Most of these studies have been performed in ovarian cancer cell lines, where 
metformin impairs cell proliferation, migration, and angiogenesis potential and 
enhances the chemotherapy sensibility [33–36].
The direct antitumoral effects of metformin are commanded by metabolic 
changes in cancer cells. Because metformin is a drug with pleiotropic effects, several 
molecular targets at different levels of the tumoral cell have been described. One of 
the most studied targets for metformin is the adenosine monophosphate-activated 
protein kinase (AMPK), a key sensor of the energetic status of the cell [37], and it 
was described that metformin treatment can activate AMPK in in vitro and in vivo 
experiments of ovarian cancer models [33, 38]. The activation of AMPK occurs by 
increasing the AMP/ATP ratio [39] which exposes the activation loop of AMPK to 
be phosphorylated in the residue threonine 172 by serine/threonine kinases such as 
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liver kinase B1 (LKB1) [40]. Activated AMPK phosphorylates several proteins; the 
phosphorylation can either activate or repress protein function at the cellular level 
[41, 42]. Despite that an important part of the studies indicates that the antitumoral 
effect of metformin could be AMPK-dependent; in the absence of AMPK, metfor-
min preserves most of its antitumoral effects [43], indicating that the mechanism of 
this drug is more complex.
3.2 Antiproliferative mechanism of metformin in ovarian cancer cells
One of the characteristic hallmarks of cancer cells is an increased cell prolif-
eration. To do so, ovarian cancer cells overexpress several growth factors and its 
receptors, which produce an enhanced cell signaling related with survival and 
proliferation in these cells [44–46].
In ovarian cancer, growth factors can activate protein kinase B (AKT) and the 
extracellular signal-regulated kinase (ERK) signaling pathways, among others 
[47–49]. These signaling pathways are associated with an increase of cell prolifera-
tion in most kinds of cancer cells [50, 51]. Some studies have shown that metformin 
treatment decreases IGF-1 and insulin levels, in a mice model with ovarian cancer 
[51], and also metformin treatment blocks the pro-tumoral effects of the nerve 
growth factor (NGF) in epithelial ovarian cancer cells [35] or the insulin/IGF-I 
signaling in uterine serous carcinoma [52].
The activation by growth factors of AKT and ERK signaling in ovarian 
cancer cells induces the activation of mechanistic target of rapamycin complex 
1 (mTORC1), which controls protein translation and cell growth [53–55]. It is 
described that metformin-activated AMPK inhibits mTORC1 signaling in ovar-
ian cancer cells [56, 57], which could impair its cell potential to proliferate and 
fend it in unfavorable conditions. Additionally, one key point in the antitumoral 
effect of metformin is that AMPK decreases the signaling pathways mediated by 
AKT and ERK in several types of cells, including cancer cells [38, 57, 58]. These 
signaling pathways are associated with the increase of most oncoproteins, for 
example, the transcription factor c-MYC and the inhibitory apoptotic protein 
survivin (BIRC5) [59–62]. c-MYC is a proto-oncogene that controls several 
genes related with cell growth and cell proliferation, and some reports show that 
metformin decreases c-MYC protein levels in ovarian cancer cell lines [63, 64]. In 
addition, metformin decreases the mRNA levels of survivin in metastatic ovarian 
cancer cells [65].
According to current evidences, c-MYC controls the transcription and cell 
cycle inhibitors [66]. In agreement with the metformin-depending decrease of 
c-MYC in ovarian cancer cells, metformin induces the degradation of cyclin D1 
[33, 38], a protein required for progression from G1 to S phase of the cell cycle, 
and increases p21 expression (a negative regulator of cell cycle) [67]. These 
results are consistent with experiments performed in primary ovarian cancer cell 
cultures and ovarian cancer cell lines, which show that metformin induces cell 
cycle arrest in the G0/G1 phase and decreases the percentage of cells in S phase 
of the cellular cycle [35, 68, 69]. These findings highly suggest that metformin 
decreases the progression of the cell cycle in ovarian cancer cells.
Even more, several authors have shown that metformin can elicit cytostatic or 
cytotoxic effects in ovarian cancer cells. A key point for a better understanding of 
these differences is that metformin inhibits tumor cell proliferation in the presence 
of glucose (with a cytostatic effect) but induces apoptosis in low-glucose condi-
tions [70]. For example, ovarian cancer cells are more sensitive to metformin at 
concentrations of 2.5 millimolar than in 25 millimolar of glucose (found in culture 
conditions). This is a consequence of reactive oxygen species accumulation, which 
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increase cell apoptosis and endoplasmic reticulum stress and decrease of c-MYC 
protein levels [63, 70].
3.3 Effect of metformin in lipid metabolism of ovarian cancer cells
For cell proliferation, the cancer cell has high requirements of substrates for 
synthesis of structural components and signaling. One target of AMPK is the sterol 
regulatory element-binding protein 1 (SREBP1), a lipogenic transcription factor 
[71], which increases cellular biosynthesis of fatty acids and cholesterol by tran-
scription of the enzymes ACC, HMG-CoA reductase, and fatty acid synthase [72], 
not only in fat tissue but also in ovarian cancer cells [73]. Because ACC is involved 
in the taxol-mediated cytotoxic effect of ovarian cancer cells [74], besides the fact 
that the inhibition of ACC suppresses ovarian cancer cell growth in vivo and in vitro 
[75], it is possible to conclude that ACC inhibition could contribute to an important 
part of the antitumoral effects of metformin.
3.4 Anti-angiogenic activity of metformin in ovarian cancer
Angiogenesis, defined as the generation of new blood vessels from preexisting 
ones [76], is an essential process to supply oxygen and nutrients to normal and 
tumoral ovarian cells. Unfortunately, this process is exacerbated in ovarian cancer 
cells, which overexpress some growth factors, such as vascular endothelial growth 
factor (VEGF) or NGF [77, 78] which promotes angiogenesis.
The relevance of metformin in the vascular context is recognized; however, 
its action depends on the cell type, metabolic status, and nutrient availability. For 
example, some pro-angiogenic properties have been attributed to metformin under 
hypoxia and hyperglycemia, similar characteristics to myocardial infarction in 
diabetic patients. In this context, metformin enhances endothelial cell survival, 
migration, and apoptosis inhibition [79, 80]; this strongly suggests that the use of 
metformin could be beneficial in the context of cardiovascular diseases in diabetic 
patients. On the other hand, metformin could have an opposite effect in endothelial 
cells under hypoglycemic conditions (as tumor endothelial cells), where metformin 
produces an inhibition of its cell proliferation and angiogenesis potential, as will be 
discussed later.
In the ovary, the correct formation and regression of blood vessels during 
each ovarian cycle is indispensable for proper follicular development, ovulation, 
and corpus luteum formation, so that angiogenesis displays a key role in ovarian 
homeostasis and pathogenesis [81]. In patients with polycystic ovary syndrome, an 
increased expression of VEGF is described, and it is hypothesized that part of the 
beneficial metformin-associated effects will be mediated by a decrease or nor-
malization of its VEGF levels. For example, it is described that in a rat model with 
dehydroepiandrosterone-induced polycystic ovaries, metformin administration 
restores the ovarian-increased levels of VEGF and angiopoietin 1, both angiogenic 
factors [82]. In addition, women with polycystic ovarian syndrome who take 
metformin have decreased their levels of plasmatic endothelin 1 and plasminogen 
activator inhibitor-1 [83, 84], molecules that also promote angiogenesis.
The angioprotection is an antitumoral mechanism that has been explored in 
ovarian cancer. Considering that the most studied angiogenic factor is VEGF, a 
monoclonal antibody against VEGF called bevacizumab has been developed and 
was approved for the use in advanced stages of ovarian cancer [85, 86]. In ovarian 
cancer models, the main knowledge of anti-angiogenic characteristics of metformin 
comes from VEGF modulation. Several in vitro models have shown that metformin 
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decreases both VEGF mRNA and protein levels in ovarian cancer cell lines and then, 
its angiogenic potential [33, 64]. In a mice model with ovarian cancer, metformin 
decreases VEGF levels in plasma and ascitic fluid, with a consistent decrease of the 
ovarian tumor growth [51]. Interestingly, metformin reduces the vascular density 
(showed by CD31 staining) of ovarian cancer xenografts in mice, and metformin-/
cisplatin-treated mice have significantly less vascular density than either metformin 
or cisplatin alone [33]. Because cisplatin/carboplatin and paclitaxel are drugs used 
in the first-line chemotherapy in ovarian cancer [87, 88], these results suggest that 
metformin could potentiate the anti-angiogenic effects of chemotherapy during 
ovarian cancer treatment.
On the other hand, metformin treatment (in millimolar concentrations) dis-
plays direct effects in the endothelial cells, by reducing cell proliferation in human 
umbilical vein endothelial cells (HUVEC) and endothelial progenitor cells [89, 90]. 
Similar results were replicated by our group where metformin decreases cell pro-
liferation of the endothelial cell line EA.hy926, in a dose-dependent manner [35], 
as well as, the endothelial cell differentiation (Figure 1). These results suggest that 
metformin affects in a direct manner the angiogenesis potential of endothelial cells.
3.5 Posttranscriptional regulation by metformin in ovarian cancer cells
In the ovarian cell, posttranscriptional regulations control gene expression at 
RNA level [91]. The micro-RNAs (miRs) are short non-codificant RNAs that regu-
late the expression of approximately 60% of protein-coding genes of the human 
genome [92]. miRs bind to a messenger RNA target, producing its degradation or 
translational repression depending of complementary degree [93]. The machinery 
for expression, processing, and exportation of miRs depends on several proteins as 
RNAse III DICER and exportins [93]. It is described that DICER downregulation 
is an oncogenic event that enhances epithelial-mesenchymal transition (EMT) and 
metastatic dissemination in cancer cells [94]. An important antecedent is that met-
formin elicits anticancer effects through the sequential modulation of DICER and 
c-MYC in breast cancer cells, increasing oncosuppressor miRs [95]. These mecha-
nisms have not been investigated in ovarian cancer cells; nevertheless, preliminary 
results from our group show that metformin increases the oncosuppressor miRs 
23-b and miR-145 in the epithelial ovarian cells [96].
As already mentioned in point 3.3, the activation of AMPK by metformin 
produces an inhibitory phosphorylation of acetyl-CoA carboxylase, an enzyme 
that regulates lipid metabolism. Importantly, intermediaries of lipid metabolism 
participate in cell signaling and chromatin structure, modulating processes as cell 
histone acetylation that depends on cytosolic acetyl-CoA [97]. The decrease of the 
Figure 1. 
Effect of metformin on the differentiation of endothelial cells. Metformin reduces the multicellular junctions 
and polygonal structures of endothelial cells EA.hy926 in a matrigel assay (4 h). Upper insert: positive control 
(NGF 100 ng/ml). Magnification bar: 50 μm.
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conversion of acetyl-CoA to malonyl-CoA leads to an increase in the acetylation 
of histones in the chromatin and altered gene expression in ovarian cancer cells 
[67]. Because acetylation of nucleosomal histones is linked to nuclear processes as 
transcription, replication, and repair among other functions [98], it is possible that 
several antitumoral effects of metformin could be regulated by protein acetylation 
and transcriptional regulation of several oncosuppressor proteins.
The summary of the main studied antitumoral effects of metformin is shown in 
Figure 2.
3.6 Studies of metformin in diabetic patients with ovarian cancer
A recent meta-analysis shows that among available studies of relationship 
between metformin intake with ovarian cancer incidence and prognosis in dia-
betic patients, the majority of the studies indicate a negative correlation between 
the use of metformin and the incidence of ovarian cancer, as well as, a positive 
correlation with better prognosis [99]. The same study shows that metformin 
treatment in diabetic patients has a reduction of 24% risk of ovarian cancer 
occurrence and also a 42% of reduction in mortality [99]. The main studies that 
showed metformin benefits in the context of ovarian cancer diabetic patients are 
summarized in Table 1.
Figure 2. 
Main antitumoral mechanism of metformin in ovarian cancer cells. Metformin enters the cell through organic 
cationic transporters (OCT) and produces the activation of liver kinase B1 (LKB1) and an increase of AMP/
ATP ratio, which results in the activation of AMPK. This kinase has several targets as sterol regulatory 
element-binding protein 1 (SREBP) and acetyl-CoA carboxylase (ACC); the mechanistic target of rapamycin 
complex 1 (mTORC1) and AKT/ERK signaling; key proteins in the fatty acid synthesis and cell growth, 
survival, proliferation, and migration; and the processes of epithelial-mesenchymal transition (EMT). On 
the other hand, metformin can block the growth factor (GF) signaling dependent or independent of AMPK 
activation. Also metformin decreases the angiogenic potential of ovarian cancer cells, impairs the expression of 
vascular endothelial growth factor (VEGF), or acts directly on the endothelial cells.
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Although several observational studies show positive effects of metformin in 
diabetic patients, it has not yet been elucidated if metformin could be beneficial in 
nondiabetic patients. In addition, ovarian cancer has a low incidence, and the num-
ber of participants in some of the available studies is low; therefore, the evidence 
should be interpreted with caution.
Because of the increased interest in the possible use of metformin in 
nondiabetic patients, there are currently six clinical trials inscribed in NIH 
ClinicalTrials.gov database to study metformin intake in association with car-
boplatin and paclitaxel (first-line chemotherapy) in nondiabetic woman with 
ovarian cancer (NCT02312661, NCT02437812, NCT03378297, NCT02122185, 
NCT01579812, and NCT02201381) from phase 0 to phase III of the study. The 
results of one of these trials show that metformin was well tolerated and the 
outcome results were favorable, because tumors from metformin-treated women 
have a threefold decrease in specific subpopulations of ovarian cancer stem cells 
with an increased sensitivity to cisplatin in vitro [100], supporting the use of 
metformin in the following phases of the study.
Research Study and population Main finding
Wang 
et al. [12]
Retrospective cohort study 
N = 568, China
• Metformin group of OvCa patients had longer 
median PFS* than non-metformin, nondiabetic, 
and metformin-discontinued groups
• Similar PFS* in dose (500 or 1000 mg of 
metformin)
• Metformin treatment must be continuous to obtain 
beneficial effects
Bar et al. 
[114]
Retrospective cohort study 
N = 143, Israel
• Metformin was associated with a reduced risk of 
recurrence of OvCa (lower PFS*), and this associa-
tion was stronger in diabetic patients
Tseng 
et al. 
[115]
Retrospective cohort study 
N = 479,475, China
• 601 metformin ever-users and 2600 never-users 
developed OvCa (incidence of 49.4 and 146.4 per 
100,000 person-years)
• Metformin use was associated with a decreased risk 
of OvCa
Kumar 
et al. 
[116]
Case-control study 72 cases 
(OvCa, metformin users), 142 
controls (OvCa, non-metformin) 
USA
• Metformin was associated with a better survival in 
OvCa patients
• 5-year DSS** was higher in metformin group
• Metformin was an independent predictor of 
survival
Romero 
et al. 
[102]
Retrospective cohort study 
N = 341, USA
• Metformin group had a longer PFS* and overall sur-
vival of OvCa compared to nonusers or nondiabetic 
patients
• Metformin group decreased hazard for disease 
recurrence
Bodmer 
et al. 
[117]
Case-control study 1611 cases 
(OvCa) and 9170 controls (non-
OvCa), UK
Metformin use was associated with a decreased of risk 
of OvCa
*PFS: progression-free survival (length of time during and after the treatment of OvCa that a patient lives with the 
disease but it does not get worse).
**DSS: disease-specific survival (percentage of people in a study or treatment group who have not died from OvCa in 
a defined period of time).
Table 1. 
Summary of studies that evaluated incidence and prognosis of ovarian cancer (OvCa) patients using and not 
using metformin.
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3.7 Role of metformin in metastasis and chemoresistance
Besides the abovementioned benefits, metformin treatment has a relevant role 
in the metastasis and chemoresistance prevention of several ovarian cancer models. 
For example, in vitro experiments have shown that metformin decreases the adhe-
sion capacity, invasion, and migration of ovarian cancer cell lines [101]. In rodents, 
metformin treatment inhibits the growth of metastatic nodules in the lung product 
of ovarian cancer [33], and importantly, the use of metformin in diabetic women 
decreases the probability of disease recurrence [102].
The cancer stem cells, recently called “tumor-initiating cells,” are a tumoral cell 
subpopulation with critical role in therapy resistance and metastasis [103–105]. 
There are several markers to identify them, as lactate dehydrogenase (LDH), 
aldehyde dehydrogenase (ALDH), or cell-surface antigens as CD44, CD133, or 
CD117 [106–108]. Metformin treatment decreases the abundance of ovarian cancer 
LDH+ and decreases its ability to form tumor spheres, an attachment-independent 
growth characteristic of these kinds of cells [109]. At the same time, a low dose 
of metformin (micromolar concentration) decreases the abundance of CD44+/
CD117+ ovarian cancer cells selectively, whereas CD133+ or ALDH+ cell subpopu-
lation were more sensitive to millimolar concentration of this drug [109, 110].
Another key point is that metformin decreases the expression of classical mark-
ers related with EMT. This process is necessary to confer an increased migratory 
capacity to tumor cells, participating in the intra-/extravasation and hence, in the 
tumor cell dissemination. In CD44+/CD117+ ovarian cancer cells, metformin treat-
ment decreases snail2, twist, and vimentin protein levels (these are mesenchymal 
markers), increasing E-cadherin protein levels (a known epithelial marker) [110]. 
These observations are related with a study performed in diabetic patients with 
endometrial cancer, where in the biopsies of these patients using metformin were 
found increased levels of E-cadherin [111]. These findings suggest that metformin 
decreases the process of EMT in ovarian cancer cells, affecting preferentially 
tumor-initiating cells, which constitutes a relevant advantage, because this type of 
cells is not affected by traditional chemotherapy.
One important aspect in ovarian cancer treatment is the high percentage of 
chemoresistance developed by patients. In this context, metformin stands as a 
promising drug, since several studies showed that it could increase the susceptibil-
ity of ovarian cancer cells to chemotherapy and revert its acquired chemoresistance 
[34, 112, 113]. One recent study performed in ovarian cancer cell lines treated for 
6 months with cisplatin and paclitaxel (for the acquirement of chemoresistance 
phenotype) shows that metformin treatment increases drug sensitivity and reduces 
migratory abilities of these ovarian cancer cells. In addition, the same study shows 
that metformin decrease the ovarian cancer stem cell population and the expression 
of specific biomarkers of pluripotent genes [112].
3.8 Main conclusions
Metformin is an antidiabetic drug that displays antitumoral effects in several 
in vivo and in vitro models of cancer, including ovarian cancer. The mechanism of 
its antitumoral effects could be either dependent or independent of AMPK, a key 
sensor of the cell energetic status. Metformin has several cell targets which include 
transcription factors and cell cycle regulators; wherewith it impairs cell prolifera-
tion by the arrest of the cell cycle. In addition, metformin modulates enzymes 
of metabolic pathways and lipid metabolism, as well as epigenetic and posttran-
scriptional regulation of the ovarian cancer cells, which can explain its pleiotropic 
actions. Another important point is that metformin regulates angiogenesis in 
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the ovarian cancer cells, mainly decreasing VEGF expression, which impairs the 
angiogenic potential of these cells. On the other hand, metformin acts directly in 
endothelial cells, decreasing its proliferation, migration and differentiation, which 
complement its anti-angiogenic effect.
An important niche for metformin treatment could be its selective effect in ovarian 
cancer cells with stem cell phenotype, which are responsible for ovarian cancer dis-
semination and chemotherapy resistance. Several studies show that metformin reduces 
ovarian cancer stem cells abundance and that it could have a chemosensitivity role when 
used in combination with first-line chemotherapy agents. This opens the possibility to 
the potential use of metformin as a coadjuvant agent in ovarian cancer treatment.
Finally, there are several observational studies in diabetic women with ovarian 
cancer which show that metformin is associated with less ovarian cancer incidence and 
better prognosis. However, it is important to consider that the number of participants 
using metformin in some of these studies is low and that several in vitro experiments 
have shown that metformin action depends on the metabolic context and nutrient and 
oxygen availability of ovarian cancer cells. For these reasons, the use of metformin in 
nondiabetic women with ovarian cancer should be considered with caution.
Currently, there are several clinical trials performed in women with ovarian 
cancer. These trials are studying the effect of metformin treatment together with 
standard chemotherapy in the ovarian cancer prognosis and clinic-pathological 
markers, which could be helpful to elucidate whether this drug could be considered 
as a coadjuvant alternative in the treatment of ovarian cancer.
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Appendices and nomenclature
ACC acetyl-CoA carboxylase
AKT activate protein kinase B
AMPK adenosine monophosphate-activated protein kinase
ALDH aldehyde dehydrogenase
EMT epithelial-mesenchymal transition
ERK extracellular signal-regulated kinase
HUVEC human umbilical vein endothelial cells
IGF insulin-like growth factor
LDH lactate dehydrogenase
LKB1 liver kinase B1
mTORC1 mechanistic target of rapamycin complex 1
miRs micro-RNAs
NGF nerve growth factor
OCTs organic cationic transporters
SREBP1 sterol regulatory element-binding protein 1
VEGF vascular endothelial growth factor
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